Genomic Data Platform

What a Genomic Data Platform is

A genomic data platform serves teams working with whole genomes, exomes, and gene panels. It links samples to sequenced data, runs variant detection and annotation, and supports interpretation: deciding which variants matter for a research question or a patient's care.

Its distinguishing challenge is interpretation at scale. A single genome contains millions of variants, almost all irrelevant, so the platform must filter, annotate, and prioritise variants against population, clinical, and functional evidence, and must record the reasoning behind every interpretation.

Core features

Genomic features turn millions of variants into interpretable, evidence-backed findings.

• Sample and sequence management: Link samples, consent, and sequencing runs to stored genomic data, with versioned references and data-quality metrics per sample.
• Variant detection and annotation: Run variant detection pipelines and annotate variants with population frequency, predicted effect, and clinical database entries.
• Variant filtering and prioritisation: Filter variants by frequency, inheritance, gene panel, and predicted impact, so reviewers focus on candidates that could matter.
• Interpretation workspaces: Support collaborative variant review with classification, evidence notes, and sign-off, preserving the reasoning behind each decision.
• Report generation: Generate research or clinical reports from interpreted variants, with version control so a report can always be traced to its data and interpretation.
• Consent and access control: Enforce consent-based access to genomic data, so sensitive data is visible only to authorised users for approved purposes.

How it is built

Build sample linkage and variant annotation first, since interpretation without trustworthy data foundations misleads reviewers.

1. Data model design: Define sample, consent, sequence, and variant records, validated with genomic scientists and clinicians.
2. Pipeline core: Build variant detection and annotation pipelines with versioned references and quality metrics.
3. Filtering and review: Add variant filtering, prioritisation, and collaborative interpretation workspaces.
4. Reporting: Add report generation with version control and audit trails.
5. Access and scale: Add consent-based access controls and scalable storage for growing genomic cohorts.

Technology considerations

Genomic platforms need large-scale storage, compute for variant pipelines, and careful handling of sensitive data. They must also manage reference and annotation database versions, since interpretation changes when evidence databases update.

• Variant pipelines with versioned references and annotation sources
• Large-scale genomic storage with efficient cohort querying
• Evidence-based variant prioritisation and filtering
• Interpretation workspaces with classification audit trails
• Consent-based access control for sensitive genomic data

Challenges to plan for

Genomic platforms fail on interpretation quality and data governance before they fail on storage.

• Evidence currency: Clinical and population databases update constantly. Version annotation sources and re-annotate cohorts deliberately, not silently.
• Interpretation consistency: Different reviewers classify the same variant differently. Structured evidence capture and review workflows improve consistency.
• Consent complexity: Genomic consent varies by participant and purpose. Enforce consent at query time, not only at data ingest.
• Data scale: Genomic cohorts grow into petabytes. Plan storage tiering and archival from the first release.

What to scope before you build

Before scoping, define the assay types — genome, exome, or panels — cohort size, and intended use, research or clinical, since clinical use adds reporting and validation requirements. Confirm which annotation and clinical databases matter, and how consent will be captured and enforced.

How it works in practice

A clinical team receives a patient's exome data and the platform annotates millions of variants, filtering them by population frequency, gene panel, and predicted impact down to a handful of candidates. Two reviewers examine the evidence for the leading candidate in a shared workspace, classify it with recorded reasoning, and generate a report versioned to the exact data and annotation databases used. When a database update later changes the evidence, the team can re-annotate deliberately and decide whether the classification changes, rather than discovering a silent shift. Success is measured by time to interpretation, classification consistency between reviewers, and report traceability. The platform also keeps a record of variants that were reviewed and dismissed, so future reviewers do not repeat work already done and can see why a candidate was set aside.

Frequently asked questions